BioSpace News Archive

HotSpot Therapeutics, Inc. today announced the presentation of additional preclinical data from the Company’s Casitas B-lineage lymphoma proto-oncogene (CBL-B) program in a poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Diality, Inc., a medical technology company developing a user-friendly, mobile, and connected hemodialysis system with a category-leading prescription range, announced plans for a clinical trial to support a home use indication for its Moda-flx Hemodialysis System.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”) today announced the presentation of new preclinical data from the company’s CLD-201 (SuperNova) allogeneic stem cell-based platform and announces readiness for clinical trial launch in 2024 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.

TG Therapeutics, Inc. announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology Conference, being held at the JW Marriott Essex House, in New York City on November 6 -7, 2023.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended September 30, 2023, and provided a business update.

Sumitomo Pharma America, Inc. (SMPA) today announced preliminary clinical data for investigational agents TP-3654, a selective oral PIM1 kinase inhibitor, and DSP-5336, an inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction.

Sonoma Pharmaceuticals, Inc. announced the U.S. launch of its intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.

Panbela Therapeutics, Inc. announced it has entered into agreements with certain holders of its existing warrants exercisable for 2,130,000 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $0.78 per share, in exchange for new warrants as described below.